“Veld fires start from glowing ash: The numbers dismissed today as small, can offset the gains made in the national HIV response in the near future.” By Catherine Murombedzi (Internews Health Journalism Network, Mercury Phoenix Trust HIV/AIDS 2023 Fellowship) ZIMBABWE should set aside domestic financial resources to deal with the rising number of people living with HIV (PLHIV) resistant to the treatment of first resort, commonly known as the first line treatment. Donors do not fund second and third line treatment drugs, making this a key health priority for the…
Read MoreTag: Dr Enerst Chikwati
Giliead Under Fire For Withholding PrEP Patents
United States (US) headquartered pharmaceutical company Gilead Sciences, is being accused of engaging in inhuman practices of holding on to patents for certain lifesaving drugs, a situation that has condemned millions to new HIV infections and premature deaths. By Kudakwashe Pembere Some of the practices include ever-greening of medicine patents like Truvada which has been in use as a pre-exposure prophylaxis (PrEP) in many countries like Zimbabwe as well as opening the license for the generic production of the hepatitis C drug Harvoni to all low- and middle-income countries. AIDS…
Read More